Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of sacubitril/valsartan on cardiac remodeling compared with other renin-angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples.
Carluccio E, Dini FL, Correale M, Dattilo G, Ciccarelli M, Vannuccini F, Sforna S, Pacileo G, Masarone D, Scelsi L, Ghio S, Tocchetti CG, Mercurio V, Brunetti ND, Nodari S, Ambrosio G, Palazzuoli A; Working Group on Heart Failure of the Italian Society of Cardiology. Carluccio E, et al. Among authors: scelsi l. Clin Res Cardiol. 2024 Jun;113(6):856-865. doi: 10.1007/s00392-023-02306-0. Epub 2023 Sep 21. Clin Res Cardiol. 2024. PMID: 37733084 Free PMC article.
Riociguat for the treatment of pulmonary arterial hypertension.
Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ; PATENT-1 Study Group. Ghofrani HA, et al. N Engl J Med. 2013 Jul 25;369(4):330-40. doi: 10.1056/NEJMoa1209655. N Engl J Med. 2013. PMID: 23883378 Free article. Clinical Trial.
Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis.
Distler O, Ofner C, Huscher D, Jordan S, Ulrich S, Stähler G, Grünig E, Held M, Ghofrani HA, Claussen M, Lange TJ, Klose H, Rosenkranz S, Vonk-Noordegraaf A, Vizza CD, Delcroix M, Opitz C, Pausch C, Scelsi L, Neurohr C, Olsson KM, Coghlan JG, Halank M, Skowasch D, Behr J, Milger K, Remppis BA, Skride A, Jureviciene E, Gumbiene L, Miliauskas S, Löffler-Ragg J, Wilkens H, Pittrow D, Hoeper MM, Ewert R. Distler O, et al. Among authors: scelsi l. Rheumatology (Oxford). 2024 Apr 2;63(4):1139-1146. doi: 10.1093/rheumatology/kead360. Rheumatology (Oxford). 2024. PMID: 37462520 Free PMC article.
Defining the clinical validity of genes reported to cause pulmonary arterial hypertension.
Welch CL, Aldred MA, Balachandar S, Dooijes D, Eichstaedt CA, Gräf S, Houweling AC, Machado RD, Pandya D, Prapa M, Shaukat M, Southgate L, Tenorio-Castano J; ClinGen PH VCEP; Chung WK; International Consortium for Genetic Studies in Pulmonary Arterial Hypertension (PAH-ICON) at the Pulmonary Vascular Research Institute (PVRI). Welch CL, et al. Genet Med. 2023 Nov;25(11):100925. doi: 10.1016/j.gim.2023.100925. Epub 2023 Jul 5. Genet Med. 2023. PMID: 37422716 Free PMC article.
[ANMCO/SIC Consensus statement on pulmonary arterial hypertension].
Vatrano M, Manzi G, Picariello C, D'Alto M, Enea I, Ghio S, Caravita S, Argiento P, Garascia A, Vitulo P, Gabrielli D, Agostoni P, Corda M, Sinagra G, Grimaldi M, Scelsi L, Badagliacca R, D'Agostino C, Perrone Filardi P, Colivicchi F, Indolfi C, Roncon L, Galiè N, Oliva F, Vizza CD. Vatrano M, et al. Among authors: scelsi l. G Ital Cardiol (Rome). 2024 Mar;25(3):192-201. doi: 10.1714/4209.42007. G Ital Cardiol (Rome). 2024. PMID: 38410902 Italian.
Gaps in evidence in the management of patients with intermediate-risk pulmonary arterial hypertension: Considerations following the ESC/ERS 2022 guidelines.
D'Alto M, Badagliacca R, Airò E, Ameri P, Argiento P, Garascia A, Lombardi CM, Mulè M, Raineri C, Scelsi L, Vizza CD, Ghio S. D'Alto M, et al. Among authors: scelsi l. Vascul Pharmacol. 2024 Jun;155:107374. doi: 10.1016/j.vph.2024.107374. Epub 2024 Apr 18. Vascul Pharmacol. 2024. PMID: 38642596 Review.
Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus.
Manzi G, Benza RL, Argiento P, Casu G, Corda M, Correale M, D'Alto M, Galgano G, Garascia A, Ghio S, Gomberg-Maitland M, Mulé M, Paciocco G, Papa S, Prati D, Preston IR, Raineri C, Romeo E, Scelsi L, Stolfo D, Vitulo P, White RJ, Badagliacca R, Vizza CD. Manzi G, et al. Among authors: scelsi l. Vascul Pharmacol. 2024 Dec;157:107432. doi: 10.1016/j.vph.2024.107432. Epub 2024 Sep 10. Vascul Pharmacol. 2024. PMID: 39265796 Review.
Author Correction: Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood.
Kariotis S, Jammeh E, Swietlik EM, Pickworth JA, Rhodes CJ, Otero P, Wharton J, Iremonger J, Dunning MJ, Pandya D, Mascarenhas TS, Errington N, Thompson AAR, Romanoski CE, Rischard F, Garcia JGN, Yuan JX, An TS, Desai AA, Coghlan G, Lordan J, Corris PA, Howard LS, Condliffe R, Kiely DG, Church C, Pepke-Zaba J, Toshner M, Wort S, Gräf S, Morrell NW, Wilkins MR, Lawrie A, Wang D; UK National PAH Cohort Study Consortium. Kariotis S, et al. Nat Commun. 2022 Nov 25;13(1):7276. doi: 10.1038/s41467-022-33381-y. Nat Commun. 2022. PMID: 36433938 Free PMC article. No abstract available.
169 results